Angiographic findings of everolimus-eluting as compared to sirolimus-eluting stents: Angiographic sub-study from the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET)

Cardiovascular Intervention and Therapeutics

Volumn 28, Issue 4, 2013, Pages 344-351

  Kozuma, Ken ^a   Kimura, Takeshi ^b   Kadota, Kazushige ^c   Suwa, Satoru ^d   Kimura, Kazuo ^e   Iwabuchi, Masashi ^f   Kawai, Kazuya ^g   Miyazawa, Akiyoshi ^a   Kawamura, Masaki ^h   Nakao, Koichi ⁱ   Asano, Ryuta ^j   Yamamoto, Takashi ^k   Suzuki, Nobuaki ^a   Aoki, Jiro ^l   Kyono, Hiroyuki ^a   Nakazawa, Gaku ^m   Tanabe, Kengo ^l   Morino, Yoshihiro ^m   Igarashi, Keiichi ⁿ  

^a TEIKYO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

^d JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^e YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^f KOKURA MEMORIAL HOSPITAL   (Japan)

^g Chikamori Hospital   (Japan)

^h MIE UNIVERSITY   (Japan)

ⁱ SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^j Sakakibara Memorial Hospital   (Japan)

^k SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^l MITSUI MEMORIAL HOSPITAL   (Japan)

^m TOKAI UNIVERSITY HOSPITAL   (Japan)

ⁿ Hokkaido Social Insurance Hospital   (Japan)

more..

Author keywords

Drug eluting stents; Fracture; Late loss; Restenosis

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY DEVICE; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS;

AGED; AGED, 80 AND OVER; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84885191873     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-013-0179-7     Document Type: Article

References (32)

1. Kotani J, Ikari Y, Kyo E, Nakamura M, Yokoi H, Furuno K, et al. Five-year outcomes of Cypher coronary stent: report from J-PMS Study. Cardiovasc Interv Ther. 2012;27: 63-71.
2. Kimura T, Morimoto T, Nakagawa Y, Kadota K, Nozaki Y, Tada T, et al. Antiplatelet therapy and long-term clinical outcome after sirolimus-eluting stent implantation: 5-year outcome of the j-Cypher registry. Cardiovasc Interv Ther. 2012;27: 181-8.
3. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58: 19-25.
4. Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58: 11-8.
5. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation. 2011;124: 886-92.
6. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA J Am Med Assoc. 2008;299: 1903-13.
7. Serruys P, Ruygrok P, Neuzner J, Piek J, Seth A, Schofer J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroInterv. 2006;2: 286-94.
8. Sabate M, Costa MA, Kozuma K, Kay IP, van der Giessen WJ, Coen VL, et al. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation. 2000;101: 2467-71.
9. Waksman R, White RL, Chan RC, Bass BG, Geirlach L, Mintz GS, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 2000;101: 2165-71.
10. Costa MA, Angiolillo DJ, Tannenbaum M, Driesman M, Chu A, Patterson J, et al. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol. 2008;101: 1704-11.
11. Liu J, Maehara A, Mintz GS, Weissman NJ, Yu A, Wang H, et al. An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol. 2009;103: 501-6.
12. Canan T, Lee MS. Drug-eluting stent fracture: incidence, contributing factors, and clinical implications. Catheter Cardiovasc Interv. 2010;75: 237-45.
13. Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011;123: 2382-91.
14. Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation. 2012.
15. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzari DE, Leon MB. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. Am J Cardiol. 2009;103: 923-9.
16. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346: 1773-80.
17. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroInterv. 2005;1: 219-27.
18. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349: 1315-23.
19. Ikari Y, Kotani J, Kozuma K, Kyo E, Nakamura M, Yokoi H. Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS). Circ J. 2009;73: 1038-44.
20. Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, et al. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv. 2011;4: 327-35.
21. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, et al. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv. 2011;4: 1096-103.
22. Sakakibara T, Ishii H, Toriyama T, Aoyama T, Takahashi H, Kamoi D, et al. Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis. Circ J. 2012;76: 351-5.
23. Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation. 2012;125: 1246-55.
24. Sakurai R, Ako J, Morino Y, Sonoda S, Kaneda H, Terashima M, et al. Predictors of edge stenosis following sirolimus-eluting stent deployment (a quantitative intravascular ultrasound analysis from the SIRIUS trial). Am J Cardiol. 2005;96: 1251-3.
25. Kang SJ, Ahn JM, Kim WJ, Lee JY, Park DW, Lee SW, et al. Intravascular ultrasound assessment of drug-eluting stent coverage of the coronary ostium and effect on outcomes. Am J Cardiol. 2013.
26. Kozuma K, Costa MA, Sabate M, Kay IP, Marijnissen JP, Coen VL, et al. Three-dimensional intravascular ultrasound assessment of noninjured edges of beta-irradiated coronary segments. Circulation. 2000;102: 1484-9.
27. Kuramitsu S, Iwabuchi M, Haraguchi T, Domei T, Nagae A, Hyodo M, et al. Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. Circ Cardiovasc Interv. 2012;5: 663-71.
28. Nakazawa G, Finn AV, Vorpahl M, Ladich E, Kutys R, Balazs I, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol. 2009;54: 1924-31.
29. Kon H, Sakai H, Otsubo M, Takano H, Okamoto K, Sato T, et al. Contrast staining outside the sirolimus-eluting stent leading to coronary aneurysm formation: a case of very late stent thrombosis associated with hypersensitivity reaction. Circ Cardiovasc Interv. 2011;4: e1-3.
30. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120: 391-9.
31. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57: 390-8.
32. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109: 701-5.